Goodman Noah sold $248K of KYMR
Goodman Noah (Chief Business Officer) sold 2,500 shares of Kymera Therapeutics, Inc. (KYMR) at $99.00 ($0.25M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is a scheduled open-market transaction under a Rule 10b5-1 plan, which generally lowers the probability of a strong negative read-through.
Market read
Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a major repricing absent additional company-specific news.
What to watch
The filing doesn’t indicate whether other insiders or institutions are buying/selling, nor does it provide context for the sale beyond the plan; without follow-on news, signal quality is limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Kymera Therapeutics, Inc.
Ticker impact
Kymera Therapeutics insider Form 4 shows CBO Noah Goodman sold 2,500 shares at $99.00 on 2026-06-22 under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this sale; any impact would be sentiment-driven and short-lived.
The filing is a primary SEC Form 4 disclosure, but it explicitly states a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal; this is company-specific insider transaction with no sector-wide regulatory/clinical catalyst mentioned.
None indicated.
None indicated.
Counterpoint
Because it’s a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish fundamentals; traders may ignore it unless paired with other negative catalysts.
Key entities
- issuerKymera Therapeutics, Inc.
Subject of the Form 4 insider transaction; CBO Noah Goodman sold shares under a 10b5-1 plan.
- insiderNoah Goodman
Chief Business Officer who sold 2,500 shares at $99.00 on 2026-06-22.
